WHO International Histological Classification of Tumours Tentative Histological Classification of Salivary Gland Tumours

Seifert, G.; Brochériou, C; Cardesa, Antonio; Eveson, J.W.

doi:10.1016/s0344-0338(11)80220-7

Cited by 291 publications

(193 citation statements)

References 71 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Adjusted for each other, the ln (hazard ratios) are 0.73 (Ϯ 0.15) for PS2, 0.93 (Ϯ 0.35) for spill, and 1.01 (Ϯ 0.49) for clinical grade of malignancy according to the 1991 WHO classification. 9,10 Testing the proportional hazards assumption, no indication for a changing prognostic value of PS1 in time was found. We found no evidence of nonlinearity of the relation between PS1 and ln (hazard) (P ϭ 0.36).…”

Section: Consideration Of Other Variablesmentioning

confidence: 97%

Prognostic index for patients with parotid carcinoma

Poorten

Hart

Laan

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDValidation of the prognostic indices for the recurrence‐free interval of patients with parotid carcinoma, the development of which was described in a previous report, is needed to be confident of their generalizability and justified prospective use.METHODSThe Dutch Cooperative Group on Head and Neck Cancer database contains 231 patients with parotid carcinoma from six tertiary referral centers who were seen between 1985–1994. This database was used to validate the predictive value of the prognostic indices, PS1 (pretreatment index predicting recurrence) and PS2 (posttreatment index predicting recurrence), in patients with parotid carcinoma. Validation methods included calculation of both indices for each patient, comparison of coefficients, construction of survival curves using the published cutoff points, and calculation of concordance measure C. Wald tests for optimization of scale and weights of the contributing variables, and for possible score improvement by including other variables, were also performed.RESULTSThe 5‐year disease‐free rate was 62% (standard error = 4%). PS1 was calculated for 183 patients. The previously set cutoff points resulted in 5‐year disease‐free rates that ranged from 92% (PS1 = 1) to 42% for the least favorable group (PS1 = 4). Concordance measure C was 0.74. The postoperative score, PS2, was calculated for 171 patients. Previous cutoff points resulted in 5‐year disease‐free rates that ranged from 90% (PS2 = 1) to 40% (PS2 = 4). Concordance measure C was 0.71. Both PS1 and PS2 did not improve using the findings in this independent material.CONCLUSIONSThe prognostic indices performed adequately in this validation sample. This finding demonstrates that the prognosis of a parotid carcinoma patient can be quantified by using a weighted combination of the parameters of age, pain, clinical T (cT) classification, clinical N (cN) classification, skin invasion, facial nerve dysfunction, perineural growth, and involved surgical margins. A quantified prognosis, in terms of the recurrence‐free interval, can be used to provide information to the patient, to perform clinical trials, and eventually to make clinical decisions. A user‐friendly translation and computerized calculation of the indices should be the next step toward generalized prospective use and repetitive evaluation of the indices. Cancer 2003;97:1453–63. © 2003 American Cancer Society.DOI 10.1002/cncr.11254

show abstract

Section: Consideration Of Other Variablesmentioning

confidence: 97%

Prognostic index for patients with parotid carcinoma

Poorten

Hart

Laan

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

“…Ultrasonography indicated enlarged or necrotic lymph nodes in the submandibular and superior internal jugular region. Therefore, this lesion was classified as cT4N2bM0 according to the World Health Organization International Classification of Tumors (21). An incisional biopsy was performed under local anesthesia, and the histopathological examination revealed SDC.…”

Section: Case Reportmentioning

confidence: 99%

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.

show abstract

“…None of the patients had received preoperative chemotherapy or radiotherapy. Tumors were classi®ed according to Seifert et al (1990). Clinical and histopathological data were available for all cases.…”

Section: Tumor Specimensmentioning

confidence: 99%

A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas

et al. 1998

View full text Add to dashboard Cite

Deletions within chromosome 6 (6q25 to 6qter) are the most consistent structural change observed in salivary gland carcinomas. To better de®ne the location of these deletions we investigated loss of heterozygosity (LOH) for 23 polymorphic markers within 19 salivary gland carcinomas covering several histological subtypes. LOH was observed in 47% of tumors, con®rming previous reports that such losses are frequent and occur in almost all histological subtypes of tumors. The highest frequency of LOH was found at, or distal to, D6S437. Seven tumors had allelic losses for D6S297 and/or D6S37. A second peak of loss was also observed at D6S262 and D6S32. In some tumors we observed LOH in one or the other of these two regions. In other tumors we observed loss of both regions with retention of intervening loci. These data suggest that two small deletions commonly occur, one between D6S262 and D6S32 (estimated to cover less than 1.5 Mb) and another between D6S297 and D6S446 (estimated to cover *2 Mb). These results extend previous studies by sublocalizing the regions of LOH and suggest that inactivation of one or more tumor suppressor genes located in these regions may be an important step in salivary gland carcinogenesis.

show abstract

WHO International Histological Classification of Tumours Tentative Histological Classification of Salivary Gland Tumours

Cited by 291 publications

References 71 publications

Prognostic index for patients with parotid carcinoma

Prognostic index for patients with parotid carcinoma

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas

Contact Info

Product

Resources

About